Particle.news

GPs Report Patchy Flu Vaccine Deliveries in Germany

Later production and delayed batch testing have strained local stocks, risking timely protection for older adults.

Overview

  • General practitioners reported on Saturday that many practices received influenza vaccine shipments late or in smaller quantities than ordered, with age‑specific products for people 60 and over most affected.
  • The Paul‑Ehrlich‑Institut confirmed it began batch testing later than usual this year but said it had released 20.2 million doses by early November and did not see a nationwide shortage.
  • Manufacturers and the national pharmacy association attributed the problem to later production and later batch release, while Sanofi said its high‑dose vaccine Efluelda was delivered on schedule.
  • Practices must order vaccine doses roughly six to nine months ahead, which forces long forecasts, limits rapid restocking and leaves clinics exposed to financial loss if demand is misjudged.
  • The delivery gaps are already creating extra work for staff — calling pharmacies and postponing appointments — and risk slowing the campaign for high‑risk groups unless supply timing or ordering rules change.